BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 32374962)

  • 1. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.
    Locatelli F; Jordan MB; Allen C; Cesaro S; Rizzari C; Rao A; Degar B; Garrington TP; Sevilla J; Putti MC; Fagioli F; Ahlmann M; Dapena Diaz JL; Henry M; De Benedetti F; Grom A; Lapeyre G; Jacqmin P; Ballabio M; de Min C
    N Engl J Med; 2020 May; 382(19):1811-1822. PubMed ID: 32374962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emapalumab: First Global Approval.
    Al-Salama ZT
    Drugs; 2019 Jan; 79(1):99-103. PubMed ID: 30623346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis.
    Garonzi C; Chinello M; Cesaro S
    Expert Rev Clin Pharmacol; 2021 May; 14(5):527-534. PubMed ID: 33686916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections.
    Lounder DT; Bin Q; de Min C; Jordan MB
    Blood Adv; 2019 Jan; 3(1):47-50. PubMed ID: 30617216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure-safety relationship for patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.
    Jordan MB; Locatelli F
    Pediatr Blood Cancer; 2024 Feb; 71(2):e30778. PubMed ID: 38014905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emapalumab for the treatment of hemophagocytic lymphohistiocytosis.
    Cheloff AZ; Al-Samkari H
    Drugs Today (Barc); 2020 Jul; 56(7):439-446. PubMed ID: 32648854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.
    Chandrakasan S; Jordan MB; Baker A; Behrens EM; Bhatla D; Chien M; Eckstein OS; Henry MM; Hermiston ML; Hinson AP; Leiding JW; Oladapo A; Patel SA; Pednekar P; Ray AK; Dávila Saldaña B; Sarangi SN; Walkovich KJ; Yee JD; Zoref-Lorenz A; Allen CE
    Blood Adv; 2024 May; 8(9):2248-2258. PubMed ID: 38429096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL).
    Merli P; Algeri M; Gaspari S; Locatelli F
    Front Immunol; 2020; 11():608492. PubMed ID: 33424859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis.
    Brossard P; Laveille C
    Rheumatol Ther; 2024 Jun; 11(3):869-880. PubMed ID: 38662147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful use of emapalumab in refractory hemophagocytic lymphohistiocytosis in a child with Chédiak-Higashi syndrome: a case report.
    AlAhmari A; Khogeer H
    J Med Case Rep; 2023 Mar; 17(1):113. PubMed ID: 36978158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated bacillus Calmette-Guérin infection.
    Tucci F; Gallo V; Barzaghi F; Ferrua F; Migliavacca M; Calbi V; Doglio M; Fratini ES; Karakas Z; Guner S; Zambelli M; Parisi C; Milani R; Gattillo S; Mazzi B; Oltolini C; Barbera M; Baldoli C; Cirillo DM; Asnaghi V; De Min C; Cicalese MP; Ciceri F; Aiuti A; Bernardo ME
    Haematologica; 2021 Feb; 106(2):641-646. PubMed ID: 32817285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Use of Emapalumab With Ruxolitinib and Dexamethasone as an Effective Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis Complicated With Multiorgan Damage and Severe Infection.
    Liang J; Xu X; Chen Z; Yu J; Tang Y
    J Pediatr Hematol Oncol; 2024 Jul; 46(5):e360-e362. PubMed ID: 38691058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy.
    Gloude NJ; Dandoy CE; Davies SM; Myers KC; Jordan MB; Marsh RA; Kumar A; Bleesing J; Teusink-Cross A; Jodele S
    J Clin Immunol; 2020 Jul; 40(5):699-707. PubMed ID: 32447592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model-based approach.
    Jacqmin P; Laveille C; Snoeck E; Jordan MB; Locatelli F; Ballabio M; de Min C
    Br J Clin Pharmacol; 2022 May; 88(5):2128-2139. PubMed ID: 34935183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis.
    Vallurupalli M; Berliner N
    Blood; 2019 Nov; 134(21):1783-1786. PubMed ID: 31537529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
    Chellapandian D; Milojevic D
    Front Pediatr; 2023; 11():1123104. PubMed ID: 36891226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afebrile S. aureus bacteremia in two patients with hemophagocytic lymphohistiocytosis receiving emapalumab/dexamethasone/etoposide.
    Singh JK; Terao MA; Sarangi S; Toth J; Toretsky JA
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29001. PubMed ID: 33751768
    [No Abstract]   [Full Text] [Related]  

  • 18. Case report: emapalumab treatment for a pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) patient with cytokine storm enabling allogeneic hematopoietic cell transplantation.
    Jia W; Chen X; Luo J; Sumbly V; Kanegane H; He Y
    Transl Pediatr; 2024 Apr; 13(4):663-672. PubMed ID: 38715677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic and Nodular Hyperinflammation in a Patient with Refractory Familial Hemophagocytic Lymphohistiocytosis 2.
    Segal JE; Daley JD; Barnum JL; Salgado CM; Reyes-Mugica M; Schneider C; Gumus S; Thakrar D; Allen SW; Canna SW
    J Clin Immunol; 2021 Jul; 41(5):987-991. PubMed ID: 33570715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience.
    Patel SA; Allewelt HA; Troy JD; Martin PL; Driscoll TA; Prasad VK; Kurtzberg J; Page KM; Parikh SH
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1722-1728. PubMed ID: 28647558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.